Search results
Results From The WOW.Com Content Network
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [ 2][ 32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. [ 44][ 45] It is authorized for ...
Percent of people of all ages who received all doses prescribed by the initial COVID-19 vaccination protocol. Two of the three COVID-19 vaccines used in the U.S. require two shots to be fully vaccinated. The other vaccine requires only one shot. Booster doses are recommended too. [2] [3] See Commons source for date of last upload.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [ 1] Work on ICD-10 began in 1983, [ 2 ...
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [ 7][ 8]
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019. [ 1] Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. [ 2][ 3][ 4] Since 2020, vaccine ...
In June 2021, Argentina agreed to buy 10 million doses of Covaxin and administer them to its citizens. [83] On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use. [2] [3] A subsequent inspection of manufacturing facilities led WHO to suspend procurement of Covaxin through UN agencies in April 2022. [23]
Technology. The vaccine consists of a version of the receptor binding domain (RBD) of the SARS‑CoV‑2 spike protein, together with the adjuvants aluminium hydroxide gel and CpG 1018. [ 2] As the RBD protein is poorly immunogenic alone, adjuvantation is essential for a RBD-based vaccine immunogenicity. [ 9]